Dependent | Significant predictors | B | SE (B) | β | t | p |
---|---|---|---|---|---|---|
Without Axis I Comorbidity as a Covariate | ||||||
EDE change: baseline to post-treatment | SF-12 MCS | −0.05 | 0.01 | −0.47 | −3.36 | 0.002 |
Treatment assignment | −1.02 | 0.35 | −0.40 | −2.88 | 0.006 | |
R 2 adj = 0.23 | ||||||
EDE change: baseline to 6-month follow-up | SF-12 MCS | −0.04 | 0.02 | −0.36 | −2.20 | 0.04 |
Treatment assignment | −0.86 | 0.40 | −0.35 | −2.13 | 0.04 | |
R 2 adj = 0.12 | ||||||
EDE change: baseline to 12-month follow-up | SF-12 PCS | 0.05 | 0.02 | 0.32 | 2.11 | 0.04 |
R 2 adj = 0.08 | ||||||
With Axis I Comorbidity as a Covariate | ||||||
EDE change: baseline to post-treatment | SF-12 MCS | −0.04 | 0.01 | −0.43 | −2.85 | 0.01 |
Treatment assignment | −0.84 | 0.36 | −0.35 | −2.31 | 0.03 | |
R 2 adj = 0.16 | ||||||
EDE change: baseline to 6-month follow-up | Treatment assignment | −0.81 | 0.44 | −0.33 | −1.87 | 0.07 |
SF-12 MCS | −0.03 | 0.02 | −0.32 | −1.82 | 0.08 | |
R 2 adj = 0.08 | ||||||
EDE change: baseline to 12-month follow-up | SF-12 PCS | 0.05 | 0.03 | 0.33 | 2.11 | 0.04 |
R 2 adj = 0.08 |